Posted by jealibeanz on April 14, 2007, at 6:12:18
Does anyone know if DOV has any plans to resume clinical trials on this anxiolytic drug? It seemed so promising. I wonder why they were having problems proving safety.
It's basically like the benzodiazepines we have now, but doesn't target the alpha-1 GABA receptors, which are responsible for sedation and memory loss.
Maybe the FDA wouldn't approve valium, xanax, klonopin, ativan, etc. if they were submitted today. Standards have changed. They're more selective. Nobody wants a repeat of the Vioxx or Phen-Phen problems.
poster:jealibeanz
thread:749708
URL: http://www.dr-bob.org/babble/20070413/msgs/749708.html